Meeting
2018 ASCO Annual Meeting
A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma(WD/DD LPS), solid tumors (ST) and lymphomas (L).
Authors
Todd Michael Bauer
Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
Todd Michael Bauer , Mrinal M. Gounder , Amy M. Weise , Gary K. Schwartz , Richard D. Carvajal , Prasanna Kumar , Oleg Zernovak , Alida Beck , Jana Doyle , Jeanne Mendell-Harary , Jarema Peter Kochan , Shuquan Chen , Patricia LoRusso , William D. Tap , Neeta Somaiah , David Michael Hyman , Funda Meric-Bernstam , David S. Hong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT01877382
Citation
J Clin Oncol 36, 2018 (suppl; abstr 11514)
DOI
10.1200/JCO.2018.36.15_suppl.11514
Abstract #
11514
Poster Bd #
259
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.
First Author: Lillian L. Siu
Poster
2013 ASCO Annual Meeting
A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
First Author: Geoffrey Shapiro
Poster
2020 ASCO Virtual Scientific Program
Phase Ib study of a novel, small-molecule MDM2 inhibitor APG-115 combined with pembrolizumab in U.S. patients with metastatic solid tumors.
First Author: Anthony W. Tolcher
Poster
2020 ASCO Virtual Scientific Program
Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.
First Author: Xing Zhang